Breast Cancer Clinical Trial
IMPACT Trial: Intervention to iMProve AdherenCe Equitably
Summary
To determine the efficacy of a multicomponent adherence intervention among participants with early-stage breast cancer on endocrine therapy and at least one oral cardiovascular disease (CVD) medication on adherence to endocrine therapy and to CVD medication at 24 weeks assessed by self-report using the Domains of Subjective Extent (DOSE)-Nonadherence questionnaire and also by pharmacy fill data assessed in the electronic health record (EHR).
Eligibility Criteria
Inclusion Criteria:
Women or men age >18 years
Diagnosed with stage I-III breast cancer prescribed endocrine therapy
Within 3-years of the end of early active treatment (e.g., surgery, chemotherapy not including human epidermal growth factor receptor 2 (HER2)-directed therapy, radiation)
Patients must be prescribed at least 1 antihypertensive or statin medication for CVD prevention
Self-report of at least some nonadherence ET or CVD medication on DOSE-Nonadherence Extent of Nonadherence questionnaire
Exclusion Criteria:
Evidence of breast cancer recurrence
Non-English or Non-Spanish speaking
Not cognitively able to complete study requirements
Do not follow with either a primary care provider or cardiologist within the New York Presbyterian Health system's Epic EHR
Inability to provide informed consent
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10032, United States More Info
Principal Investigator
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.